Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4
about
Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progressionRegulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1)Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitorsMutation testing in melanoma families: INK4A, CDK4 and INK4DTumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR dataTargeting CDK6 in cancer: State of the art and new insightsStructure of the cyclin-dependent kinase inhibitor p19Ink4dGenetic and biochemical interactions among Yar1, Ltv1 and Rps3 define novel links between environmental stress and ribosome biogenesis in Saccharomyces cerevisiae.Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesisEvidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumorsAn important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferationFunctional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus.Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells.Coupled transcriptional and translational control of cyclin-dependent kinase inhibitor p18INK4c expression during myogenesis.Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators.BRD7, a novel bromodomain gene, inhibits G1-S progression by transcriptionally regulating some important molecules involved in ras/MEK/ERK and Rb/E2F pathways.Regulation of T cell differentiation and alloimmunity by the cyclin-dependent kinase inhibitor p18ink4cUtilizing NMR to study the structure of growth-inhibitory proteins.Cell-cycle control of plasma cell differentiation and tumorigenesis.Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity.Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms.Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells.Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation.p19(INK4d) mRNA and protein expression as new prognostic factors in ovarian cancer patients.Signaling through cyclin D-dependent kinases.CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.Protein kinase CK2 is an inhibitor of the neuronal Cdk5 kinase.Human PC4 is a substrate-specific inhibitor of RNA polymerase II phosphorylation.Canine Mammary Carcinomas: A Comparative Analysis of Altered Gene Expression.Mitotic G1-G1/S phasesS-phase entry of oligodendrocyte lineage cells is associated with increased levels of p21Cip1.BOK promotes chemical-induced hepatocarcinogenesis in mice.Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma.p19Ink4d and p18Ink4c cyclin-dependent kinase inhibitors in the male reproductive axis.Association of INK4 with CDK4/6
P2860
Q22253912-ADBFB058-5B41-4E1D-9D4D-3B9DB0BC8800Q24597148-73A0B660-9611-410B-84F2-DA437C8E9C80Q24597269-573208D3-CBB5-47D8-B572-A7697CC8EBE2Q24649783-55762AE3-48ED-4811-B233-427B37A75F59Q24672116-2AA17D20-B432-498E-BDC0-1BCF439171D9Q26796499-967E4295-A2D6-45BB-B831-E9EF0F8AA3DBQ27746702-3FFB9004-0E89-430F-9F0B-43B1007BD698Q27932544-E9224FD3-0D77-425D-ABAA-6B2061EE1B77Q28144751-C6EC953B-8C6F-4930-95AF-053725D5876DQ28219514-9FD1B739-E358-4C4B-AD90-D95D71F58523Q28349872-10F4FAD0-4683-4CD1-9B86-3C7B4C39D767Q30322978-E4FF87B4-719D-487C-A6E1-3F56C346DB30Q31029691-B73D9393-802A-42C4-BE63-129F43D5FE72Q33962726-8C731A04-27ED-4C5D-AF3E-853DACE63644Q33996518-9811EBDC-D9D8-401A-9754-1890D3D4010CQ34176430-FD6BD6F6-C191-4267-B4AF-D054435F3056Q34320007-7B2038D6-5D82-45E2-8F13-35B46F667989Q35116592-EEE0BC21-F439-4410-A736-0C42C9C3568AQ35141470-A8375445-A78B-437A-9EE0-5738B8839DAAQ35170909-6BAAE2D6-FB3F-4116-9599-EA6C5F5809A3Q35783591-F4E03372-1BD2-4C47-9DEB-ED2FF92973D1Q36994751-1ACB158E-8806-4E3A-B589-4EE108FD4CCBQ37378963-F73D96C7-A593-4645-B7D1-4668669205CAQ37382933-90B756BF-53CA-4C90-9FC0-D201628D745CQ37589242-E7A57248-1E6A-4191-9178-5AE463732498Q38104238-A740D27D-BA0D-4CC9-B240-CB371A3EAD48Q39185185-075DF250-8F48-440A-AEA6-F1BC3BB367A3Q39444740-3ACE16BE-876D-453F-B36F-EE467CCDECB6Q39444837-0E537EE4-487B-4A16-B8A8-1CEF0D7BC2BBQ40519802-11018C2F-CCE0-41CE-8BD0-2D2083D28FDEQ40897870-9C75F1BB-B8B4-4A33-8F32-8B6AB5ADA2CFQ43123105-9F47B3D2-D3D7-4160-B330-95444A31B59FQ45314017-4512F13E-2A8B-4C54-BD56-490B9874B38FQ46403137-493881B3-2653-44DB-8CF9-DD50A698313FQ47304516-0BCE58EA-55DD-4069-9846-0C5BFB02A100Q47723736-60ED5A91-C02A-4853-8A3E-A55761FC40AEQ48251487-AD05C6D2-3AFE-4792-A1BA-6920A761C69CQ50285962-AD2C7767-398D-43B3-A2FD-7381115C9442
P2860
Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Isolation and characterization ...... itor specific to CDK6 and CDK4
@ast
Isolation and characterization ...... itor specific to CDK6 and CDK4
@en
Isolation and characterization ...... itor specific to CDK6 and CDK4
@en-gb
Isolation and characterization ...... itor specific to CDK6 and CDK4
@nl
type
label
Isolation and characterization ...... itor specific to CDK6 and CDK4
@ast
Isolation and characterization ...... itor specific to CDK6 and CDK4
@en
Isolation and characterization ...... itor specific to CDK6 and CDK4
@en-gb
Isolation and characterization ...... itor specific to CDK6 and CDK4
@nl
prefLabel
Isolation and characterization ...... itor specific to CDK6 and CDK4
@ast
Isolation and characterization ...... itor specific to CDK6 and CDK4
@en
Isolation and characterization ...... itor specific to CDK6 and CDK4
@en-gb
Isolation and characterization ...... itor specific to CDK6 and CDK4
@nl
P2093
P2860
P356
P1476
Isolation and characterization ...... itor specific to CDK6 and CDK4
@en
P2093
A G Matera
C L O'Keefe
C W Jenkins
M Zariwala
P2860
P356
10.1091/MBC.7.1.57
P407
P577
1996-01-01T00:00:00Z